To address this urgent clinical need, we conducted a series of neoadjuvant clinical trials (the MUKDEN Trials), designed to explore novel treatment strategies and deepen our understanding of the molecular pathogenesis of HR+/HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.